Title

P02-36 - Effect of aripiprazole adjunctive to antidepressants on sexual functioning: A subgroup analysis of a 52-week open-label safety study (CN138–164)

Document Type

Research Poster

Publication Date

2011

Abstract

Introduction

This presentation addresses impacts of adjunctive aripiprazole (AA) in major depressive disorder (MDD).

Objective

Assess impacts of long-term (≤52 weeks) open-label AA to ADT on efficacy, sexual function and weight change in MDD.

Methods

Data were analyzed post-hoc from de novo patients enrolled in an open-label safety study of AA after inadequate response to one or more ADT. Three ADT classes were included: SSRIs, SNRIs, and a noradrenaline-dopamine reuptake inhibitor, bupropion.

Global well-being with AA was assessed (mean change in CGI-S score from baseline by ADT). Sexual functioning was assessed by Sexual Function Inventory (SFI) items: interest in sex, sexual arousal, achievement of orgasm, erection maintenance and sexual satisfaction. Item 6 captured change in the overall improvement score. Weight change at Week 52 (last observation carried forward) was assessed.

Results

Overall mean change in CGI-S (n = 285) by Week 52 was -1.5. Mean changes in CGI-S from baseline scores (4.2-4.4) were: escitalopram (n=64) -1.5, venlafaxine XL (n = 48) -1.4, sertraline (n = 39) -1.7, fluoxetine (n = 41) -1.3, paroxetine or CR (n = 37) -1.5 and bupropion XL or SR (n = 46) -1.4. Improvements on SFI items (n = 155) ranged from -0.2 (sexual satisfaction) to -0.6 (interest in sex and orgasm). Mean overall improvement score (3.8) indicated mild-to-moderate sexual dysfunction. All AA groups experienced a mean weight increase (range +1.8 kg [sertraline] to +3.3 kg [fluoxetine]).

Conclusions

AA moderately improved CGI-S scores (to a similar degree) when added to three different classes of ADTs. Sexual functioning in patients on ADT modestly improved after adding aripiprazole to ADT.

Comments

Citation: Gismondi, R., Clayton, A., Baker, R., Forbes, R., Marler, S., & Berman, R. (2011). P02-36 - Effect of aripiprazole adjunctive to antidepressants on sexual functioning: A subgroup analysis of a 52-week open-label safety study (CN138–164). European Psychiatry, 26, 631. doi:10.1016/s0924-9338(11)72337-9

Link to article on publisher's website

This poster was presented at the 19th European Congress of Psychiatry, European Psychiatric Association, March 12-15, 2011, Vienna, Austria